The discovery of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the fact that most patients with EGFR-mutant non-small cell lung cancer (NSCLC) can benefit from TKI treatment have dramatically changed the therapeutic approach for NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.